- Clinical Technology
- Adult Immunization
- Hepatology
- Pediatric Immunization
- Screening
- Psychiatry
- Allergy
- Women's Health
- Cardiology
- Pediatrics
- Dermatology
- Endocrinology
- Pain Management
- Gastroenterology
- Infectious Disease
- Obesity Medicine
- Rheumatology
- Nephrology
- Neurology
- Pulmonology
Screen Patients with Obesity for These 2 CVD Risk Factors, Says One Expert
Obesity medicine specialist and internist Alina Elperin, MD, shares why screening for obstructive sleep apnea and metabolic disease in patients with obesity is crucial.
Cardiovascular disease (CVD) is the leading cause of death in persons worldwide, making prevention of CVD a main priority for clinicians, said Alina Elperin, MD, in a recent interview with Patient Care Online. Dr Elperin is an internest and obesity medicine specialist in Evanston, Illinois, as well as a Clinical Assistant Professor at the University of Chicago Pritzker School of Medicine.
"In patients with obesity, unfortunately, the risk of heart disease or stroke or other vascular disease is considerably higher than in patients without obesity," stated Elperin. "I view obesity as one of those umbrella risk factors where it in itself causes other independent risk factors for heart disease...so preventing obesity or helping to treat obesity appropriately, really helps control all the major risk factors that play a role in cardiovascular disease."
In the video below, Dr Elperin shares 2 CVD risk factors that primary care clinicians should put at the top of the list for screening in patients with obesity.
Roche, Alnylam Advance Zilebesiran Into Phase 3 CV Outcomes Trial for Resistant Hypertension
September 9th 2025Zilebesiran’s twice-yearly dosing and sustained BP reductions could offer a new therapeutic approach for adults with resistant hypertension and high CV risk who are uncontrolled on current SOC regimens.
Oral PCSK9 Inhibitor Enlicitide Meets All End Points in Phase 3 Hypercholesterolemia Trial
September 2nd 2025At week 24, patients receiving once-daily enlicitide demonstrated statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol compared with placebo.
